Acalabrutinib Plus Bendamustine and Rituximab in Untreated MCL: Results From the Phase 3 ECHO Trial : Episode 4
Unmet Needs and Key Takeaways: ECHO Clinical Trial
Medical experts evaluate unmet needs, key insights from the Phase 3 ECHO trial, and potential obstacles in integrating the findings into existing treatment protocols.
- What is your standard of care (SOC) in this patient population?
- How does this regimen (BTKi+BR) compare in efficacy and safety to your SOC?
Recent Videos
Related Content
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025Podcast
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
